ORM-10962 (0.3 mg/kg, IV, once) pre-treatment significantly delays the development and recurrence of ventricular extrasystoles (by about 50%) or ventricular tachycardia (by about 30%) in anesthetized guinea pigs[1].
| Animal Model: | Male guinea-pigs (250-300 g)[1] |
| Dosage: | 0.3 mg/kg |
| Administration: | IV, 10 min before starting ouabain infusion |
| Result: | Significantly delayed the development of ventricular extrasystoles (from 24±1.7 min in controls to 36.6±2.7 min in the presence of the drug) or ventricular tachycardia (from 31.8±1.8 min in controls to 40.8±2.1 min in the presence of the drug). |